Christopher Granger, MD
Family Medicine · Dunlap, TNNPI 1861472110
Payments from drug & device makers
Across 54 payments — averaging $249.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics International Ltd$11K
- Medtronic$2K
- Irhythm Technologies, Inc.$227
- Novo Nordisk$213
- AbbVie$94
- AstraZeneca$55
- plus $296 from 13 others
What the payments were for
- Speaking & faculty fees$2,41518%
- Travel & lodging$9,19668%
- Food & beverage$1,81713%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics International Ltd | 5 | $10,841 |
| Medtronic | 11 | $1,731 |
| Irhythm Technologies, Inc. | 1 | $227 |
| Novo Nordisk | 12 | $213 |
| AbbVie(2 entities) | 4 | $94 |
| AstraZeneca | 3 | $55 |
| Lilly USA, LLC | 3 | $43 |
| Amgen | 2 | $34 |
| Abbott | 2 | $30 |
| Boehringer Ingelheim | 2 | $27 |
| Philips North America LLC | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Novartis | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARCTIC FRONT ADVANCE$589
- ZIO XT Patch$227
- Zio monitor$227
How this compares
$13,457 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 237 | $252,712 |
| EliquisApixaban | 429 | $233,645 |
| IngrezzaValbenazine Tosylate | 63 | $233,566 |
| JardianceEmpagliflozin | 206 | $158,273 |
| TrulicityDulaglutide | 101 | $103,090 |
| MounjaroTirzepatide | 60 | $72,297 |
| JanuviaSitagliptin Phosphate | 115 | $59,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $49,032 |
| XareltoRivaroxaban | 56 | $38,147 |
| LinzessLinaclotide | 32 | $24,011 |
| FarxigaDapagliflozin Propanediol | 24 | $23,075 |
| RexultiBrexpiprazole | 25 | $22,419 |
| Pantoprazole Sodium | 835 | $22,358 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $21,983 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $17,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $213 | $252,712237 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $43 | $175,387161 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $27 | $164,814219 claims |
| AbbVieLinzess | $94 | $24,01132 claims |
| AstraZenecaFarxiga | $55 | $23,07524 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17 | $22,41925 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $15,60128 claims |
| NovartisEntresto | $19 | $11,33936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Dunlap
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.